{"id":"https://openalex.org/W4281741048","doi":"https://doi.org/10.1136/jnnp-2022-abn.438","title":"113 Benefit-risk of ofatumumab in treatment-na\u00efve early relapsing multiple sclerosis patients","display_name":"113 Benefit-risk of ofatumumab in treatment-na\u00efve early relapsing multiple sclerosis patients","publication_year":2022,"publication_date":"2022-05-27","ids":{"openalex":"https://openalex.org/W4281741048","doi":"https://doi.org/10.1136/jnnp-2022-abn.438"},"language":"en","primary_location":{"id":"doi:10.1136/jnnp-2022-abn.438","doi":"https://doi.org/10.1136/jnnp-2022-abn.438","is_oa":false,"landing_page_url":"https://doi.org/10.1136/jnnp-2022-abn.438","pdf_url":null,"source":{"id":"https://openalex.org/S134773490","display_name":"Journal of Neurology Neurosurgery & Psychiatry","issn_l":"0022-3050","issn":["0022-3050","1468-330X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Neurology, Neurosurgery &amp; Psychiatry","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5079537507","display_name":"Jutta G\u00e4rtner","orcid":"https://orcid.org/0000-0003-4108-7109","observed_orcids":["https://orcid.org/0000-0003-4108-7109"]},"institutions":[{"id":"https://openalex.org/I4210116730","display_name":"Universit\u00e4tsmedizin G\u00f6ttingen","ror":"https://ror.org/021ft0n22","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210116730"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Jutta G\u00e4rtner","raw_affiliation_strings":["University Medical Centre G\u00f6ttingen, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Medical Centre G\u00f6ttingen, Germany","institution_ids":["https://openalex.org/I4210116730"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104805489","display_name":"Stephen L. Hauser","orcid":"https://orcid.org/0000-0002-4932-4001","observed_orcids":["https://orcid.org/0000-0002-4932-4001"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen Hauser","raw_affiliation_strings":["UCSF Weill Institute for Neurosciences, University of California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCSF Weill Institute for Neurosciences, University of California, USA","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077310868","display_name":"Amit Bar\u2010Or","orcid":"https://orcid.org/0000-0001-7179-0335","observed_orcids":["https://orcid.org/0000-0001-7179-0335","https://orcid.org/0000-0003-2931-1585"]},"institutions":[{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amit Bar-Or","raw_affiliation_strings":["Perelman School of Medicine, University of Pennsylvania, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Perelman School of Medicine, University of Pennsylvania, USA","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031171090","display_name":"Xavier Montalb\u00e1n","orcid":"https://orcid.org/0000-0002-0098-9918","observed_orcids":["https://orcid.org/0000-0002-0098-9918"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Xavier Montalban","raw_affiliation_strings":["Hospital Universitario Vall d\u2019Hebron, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Universitario Vall d\u2019Hebron, Barcelona, Spain","institution_ids":["https://openalex.org/I4210127641"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053403281","display_name":"Jeffrey A. Cohen","orcid":"https://orcid.org/0000-0001-9245-9772","observed_orcids":["https://orcid.org/0000-0001-9245-9772"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey Cohen","raw_affiliation_strings":["Mellen MS Center, Neurological Institute, Cleveland Clinic, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mellen MS Center, Neurological Institute, Cleveland Clinic, USA","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085986981","display_name":"Anne Haney Cross","orcid":"https://orcid.org/0000-0003-0829-7569","observed_orcids":["https://orcid.org/0000-0003-0829-7569"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anne Cross","raw_affiliation_strings":["Washington University School of Medicine, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Washington University School of Medicine, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041774387","display_name":"Kumaran Deiva","orcid":"https://orcid.org/0000-0002-8409-2365","observed_orcids":["https://orcid.org/0000-0002-8409-2365"]},"institutions":[{"id":"https://openalex.org/I4210162942","display_name":"Bic\u00eatre Hospital","ror":"https://ror.org/05c9p1x46","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210162942","https://openalex.org/I4405259118"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Kumaran Deiva","raw_affiliation_strings":["University Hospitals Paris Saclay, Le Kremlin Bic\u00eatre, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospitals Paris Saclay, Le Kremlin Bic\u00eatre, France","institution_ids":["https://openalex.org/I4210162942"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072651915","display_name":"Dieter Adrian H\u00e4ring","orcid":"https://orcid.org/0000-0001-5690-8710","observed_orcids":["https://orcid.org/0000-0001-5690-8710"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Dieter H\u00e4ring","raw_affiliation_strings":["Novartis Pharma AG, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052915346","display_name":"Wendy Weiqun Su","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wendy Su","raw_affiliation_strings":["Novartis Pharmaceuticals, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals, USA","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"last","author":{"id":null,"display_name":"et al","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"et al","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.4276,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.57316517,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"93","issue":"6","first_page":"A136.2","last_page":"A136"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ofatumumab","display_name":"ofatumumab","score":1.0},{"id":"https://openalex.org/keywords/relapsing-multiple-sclerosis","display_name":"relapsing multiple sclerosis","score":0.9079999923706055},{"id":"https://openalex.org/keywords/teriflunomide","display_name":"teriflunomide","score":0.7910000085830688},{"id":"https://openalex.org/keywords/anti-cd20-therapy","display_name":"anti-CD20 therapy","score":0.8659999966621399},{"id":"https://openalex.org/keywords/treatment-naive-patients","display_name":"treatment-naive patients","score":0.7699999809265137},{"id":"https://openalex.org/keywords/benefit-risk-profile","display_name":"benefit-risk profile","score":0.6349999904632568},{"id":"https://openalex.org/keywords/annualized-relapse-rate","display_name":"annualized relapse rate","score":0.8100000023841858},{"id":"https://openalex.org/keywords/disability-progression","display_name":"disability progression","score":0.5619999766349792},{"id":"https://openalex.org/keywords/gadolinium-enhancing-lesions","display_name":"gadolinium-enhancing lesions","score":0.9440000057220459},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.8379999995231628},{"id":"https://openalex.org/keywords/infection","display_name":"infection","score":0.4269999861717224},{"id":"https://openalex.org/keywords/self-injection","display_name":"self-injection","score":0.7099999785423279},{"id":"https://openalex.org/keywords/home-self-administration","display_name":"home self-administration","score":0.6269999742507935}],"concepts":[{"id":"https://openalex.org/C2777703276","wikidata":"https://www.wikidata.org/wiki/Q3077133","display_name":"Teriflunomide","level":4,"score":0.9567745923995972},{"id":"https://openalex.org/C2778714382","wikidata":"https://www.wikidata.org/wiki/Q410656","display_name":"Ofatumumab","level":4,"score":0.948352575302124},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8761902451515198},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5994404554367065},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5729659199714661},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.5678146481513977},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5190080404281616},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.44672098755836487},{"id":"https://openalex.org/C2776036978","wikidata":"https://www.wikidata.org/wiki/Q425137","display_name":"Fingolimod","level":3,"score":0.13843604922294617},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.1186622679233551},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.08221197128295898},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.06587588787078857},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/jnnp-2022-abn.438","doi":"https://doi.org/10.1136/jnnp-2022-abn.438","is_oa":false,"landing_page_url":"https://doi.org/10.1136/jnnp-2022-abn.438","pdf_url":null,"source":{"id":"https://openalex.org/S134773490","display_name":"Journal of Neurology Neurosurgery & Psychiatry","issn_l":"0022-3050","issn":["0022-3050","1468-330X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Neurology, Neurosurgery &amp; Psychiatry","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4220879604","https://openalex.org/W4386592575","https://openalex.org/W3212374725","https://openalex.org/W4389366724","https://openalex.org/W4391476303","https://openalex.org/W4394601267","https://openalex.org/W2048324178","https://openalex.org/W4290829705","https://openalex.org/W4416642664","https://openalex.org/W4200453726"],"abstract_inverted_index":{"Objective":[0],"To":[1],"evaluate":[2],"the":[3,33,47,151,163],"benefit-risk":[4],"profile":[5],"of":[6,51,145],"ofatumumab":[7,40,60,112,131,178],"treatment":[8],"in":[9,18,32,46,110,121,175],"patients":[10,57,156],"with":[11,184],"early":[12],"relapsing":[13],"multiple":[14],"sclerosis":[15],"(RMS)":[16],"subgroup":[17,37],"Phase":[19],"3":[20],"ASCLEPIOS":[21],"I/II":[22],"trials.":[23],"Methods":[24],"Key":[25],"efficacy":[26,181],"and":[27,95,123,133,141,194],"safety":[28],"outcomes":[29],"were":[30,119,128,139,148],"assessed":[31],"newly":[34],"diagnosed,":[35],"treatment-na\u00efve":[36],"who":[38],"received":[39],"or":[41],"teriflunomide":[42,134,183],"as":[43,173],"first-line":[44],"therapy":[45],"trials":[48],"(n=615,":[49],"32.7%":[50],"total":[52],"patients).":[53],"Results":[54],"Compared":[55],"to":[56,197],"on":[58],"teriflunomide,":[59],"reduced":[61],"ARR":[62],"by":[63,71,79,89,99,206],"50.3%":[64],"(0.09":[65],"vs":[66,74,82,92,102,113,182],"0.18;":[67],"p<0.001),":[68,94],"3mCDW":[69],"risk":[70,78],"38%":[72],"(10.1%":[73],"12.8%;":[75],"p=0.065),":[76],"6mCDW":[77],"46%":[80],"(5.9%":[81],"10.4%;":[83],"p=0.044),":[84],"gadolinium-":[85],"enhancing":[86],"T1":[87],"lesions/scan":[88],"95.4%":[90],"(0.02":[91],"0.39:":[93],"new/enlarging":[96],"T2":[97],"lesions/year":[98],"82.0%":[100],"(0.86":[101],"4.78,":[103],"p<0.001).":[104],"Treatment-emergent":[105],"adverse":[106],"events":[107],"(AEs)":[108],"occurred":[109],"84.7%":[111],"86.0%":[114],"teriflunomide-treated":[115],"patients;":[116],"serious":[117,136],"AEs":[118],"reported":[120],"7.0%":[122],"5.3%,":[124],"respectively.":[125,143],"Infection":[126],"rates":[127,138],"comparable":[129],"between":[130],"(56.1%)":[132],"(56.5%);":[135],"infection":[137],"1.9%":[140],"0.7%,":[142],"99.8%":[144],"injection":[146],"reactions":[147],"mild-to-moderate;":[149],"after":[150],"4th":[152],"injection,":[153],">70%":[154],"RMS":[155],"self-injected":[157],"at":[158,171],"home.":[159],"Conclusion":[160],"Ofatumumab":[161],"is":[162],"first":[164],"anti-CD20":[165],"DMT":[166],"that":[167],"can":[168],"be":[169],"self-administered":[170],"home,":[172],"demonstrated":[174],"ASCLEPIOS.":[176],"Here,":[177],"showed":[179],"superior":[180],"low":[185,190],"absolute":[186],"relapse":[187],"rates,":[188],"very":[189],"MRI":[191],"lesion":[192],"activity":[193],"prolonged":[195],"time":[196],"disability":[198],"worsening.":[199],"Funding":[200],"statement:":[201],"This":[202],"study":[203],"was":[204],"funded":[205],"Novartis":[207],"Pharma":[208],"AG,":[209],"Basel,":[210],"Switzerland.":[211],"teresa.sawtell@novartis.com":[212]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-06-13T00:00:00"}